Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
142.44
+1.19 (0.84%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Neurocrine Biosciences Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 14,479 | 14,141 | 13,820 | 12,946 | 11,482 | 8,080 | |
Market Cap Growth | 4.96% | 2.32% | 6.75% | 12.75% | 42.11% | -9.78% |
Enterprise Value | 14,551 | 13,506 | 12,878 | 12,124 | 10,966 | 7,766 |
Last Close Price | 142.44 | 141.83 | 136.50 | 131.76 | 119.44 | 85.17 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 20.88 | 29.55 | 40.49 | 51.85 | 74.32 | 90.18 |
Forward PE | 12.73 | 15.87 | 18.15 | 21.34 | 22.53 | 24.55 |
PS Ratio | 4.29 | 4.94 | 5.87 | 6.86 | 7.71 | 7.13 |
PB Ratio | 3.92 | 4.35 | 5.34 | 5.80 | 6.72 | 5.88 |
P/TBV Ratio | 14.97 | 4.35 | 5.34 | 5.91 | 6.90 | 5.88 |
P/FCF Ratio | 16.63 | 18.89 | 24.80 | 35.80 | 35.56 | 34.66 |
P/OCF Ratio | 16.12 | 18.07 | 23.21 | 33.20 | 33.83 | 31.50 |
PEG Ratio | 0.31 | 0.75 | 0.31 | 0.65 | 0.66 | 1.12 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.31 | 4.72 | 5.47 | 6.43 | 7.37 | 6.85 |
EV/EBITDA Ratio | 15.93 | 20.26 | 20.64 | 29.14 | 41.44 | 35.51 |
EV/EBIT Ratio | 16.80 | 21.22 | 21.57 | 30.71 | 44.04 | 37.38 |
EV/FCF Ratio | 16.72 | 18.04 | 23.11 | 33.53 | 33.96 | 33.32 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.13 | 0.14 | 0.18 | 0.19 | 0.15 | 0.32 |
Debt / EBITDA Ratio | 0.47 | 0.65 | 0.68 | 0.99 | 0.94 | 1.88 |
Debt / FCF Ratio | 0.53 | 0.63 | 0.82 | 1.19 | 0.81 | 1.89 |
Net Debt / Equity Ratio | 0.02 | -0.31 | -0.24 | -0.27 | -0.42 | -0.20 |
Net Debt / EBITDA Ratio | 0.08 | -1.51 | -0.99 | -1.45 | -2.74 | -1.24 |
Net Debt / FCF Ratio | 0.08 | -1.35 | -1.11 | -1.67 | -2.25 | -1.16 |
Asset Turnover | 0.73 | 0.69 | 0.68 | 0.67 | 0.67 | 0.60 |
Inventory Turnover | 14.88 | 16.90 | 15.99 | 16.48 | 14.85 | 11.71 |
Quick Ratio | 1.46 | 2.92 | 3.06 | 2.25 | 2.49 | 3.65 |
Current Ratio | 1.87 | 3.39 | 3.40 | 2.45 | 2.70 | 3.96 |
Return on Equity (ROE) | 22.09% | 16.38% | 14.16% | 12.68% | 10.03% | 7.17% |
Return on Assets (ROA) | 11.70% | 9.53% | 10.71% | 8.78% | 7.01% | 6.82% |
Return on Invested Capital (ROIC) | 20.56% | 20.50% | 23.31% | 22.75% | 17.26% | 19.95% |
Return on Capital Employed (ROCE) | 19.30% | 16.40% | 18.60% | 15.20% | 13.60% | 11.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.87% | 3.38% | 2.47% | 1.93% | 1.35% | 1.11% |
FCF Yield | 6.01% | 5.29% | 4.03% | 2.79% | 2.81% | 2.89% |
Buyback Yield / Dilution | -0.78% | 1.16% | -2.67% | -2.12% | -1.02% | -0.10% |